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A53-year-oldmanwasattendedtotheClinicOphthalmicCenter,MansouraUniversity,Egypt,withrecurrenttransientmonocular
visual loss after receiving sildenaﬁl citrate (Viagra) for erectile dysfunction. Examination for possible risk factors revealed mild
hypercholesterolemia. Family history showed that his father had suﬀered from bilateral nonarteritic anterior ischemic optic
neuropathy (NAION). Physicians might look for arteriosclerotic risk factors and family history of NAION among predisposing
risk factors before prescribing sildenaﬁl erectile dysfunction drugs.
1.Introduction
Sildenaﬁl citrate (Viagra; Pﬁzer Pharmaceuticals, New York,
NY, USA) is a selective phosphodiesterase 5 inhibitor and
partial phosphodiesterase 6 inhibitor prescribed for erectile
dysfunction. Sildenaﬁl intake leads to smooth muscle relax-
ation in the corpus cavernosum, allowing inﬂow of blood
by enhancing the eﬀect of nitric oxide and cyclic guanosine
monophosphatase pathway, during sexual intercourse. Silde-
naﬁlis rapidly absorbed withahalf-time offourhourswitha
maximum plasma level reached within half up to two hours
after oral intake [1].
Painlesstransientmonocularvisuallossisconsistentwith
an ischemia occurring repeatedly in the visual pathway ante-
rior to the chiasm. Other conditions such as intermit-
tent angle-closure glaucoma, pigment dispersion glaucoma,
optic disc drusen, and papilloedema can cause monocular
blindness. Repeated transient monocular visual loss during
sexual intercourse has been reported in relation to subacute
angle closure [2], and to hypothetical retinal vasospasm
[3]. This case revealed transient monocular visual loss in
male patient with hypercholesterolemia, and family history
of NAION with the use sildenaﬁl citrate (Viagra) for erectle
dysfunction.
2.CaseReport
A nonsmoker 53-year-old man used sildenaﬁl citrate (Via-
gra) for erectile dysfunction. History recording tells that he
had been using this drug for the last four months at least
once a week. The patient had no past medical history related
to cardiovascular or erectile disorders and did not take any
other treatment. The patients had no history of alcohol
intake.
The patient complained of transient painless blurred vi-
sion in his left eye, recurring after sexual intercourse, two or
three times. Each attack of transient monocular blindness
lasted 2-3 minutes, then followed by spontaneous visual
recovery. The vision was not disturbed in the fellow eye.
Ophthalmic examination revealed a corrected visual acuity
of 10/10 for the right eye and 2/10 for the left eye. Pupils
reaction revealed a relative aﬀerentpupillary defectof theleft
pupil. Slit-lamp biomicroscopy of the anterior segments of
both eyes was normal, including angles, and did not show
any pathological manifestations. Intraocular pressure (IOP)
was 16mmHg for both eyes. The color vision score for the
aﬀected left eye was 9 out of 15 Ishihara plates, while the
unaﬀected right eye had a score of 15 out of 15. General
andneurologicalassessmentsrevealednoabnormalﬁndings.2 Case Reports in Ophthalmological Medicine
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Figure 1: Nonarteritic anterior ischemic optic neuropathy (NAION) in the left eye of a 53-year-old man patient with a history of
hypercholesterolemia. The right optic disk is pink and ﬂat (a). Automated perimetry, using the Humphrey visual ﬁeld 24-2 protocol, shows
a normal visual ﬁeld (b), with the dark spot in the temporal ﬁeld being the physiologic blind spot. Acutely, the left optic disk appears swollen
and hyperemic, with hemorrhage at the superior and temporal disk margin (c). Automated perimetry shows diﬀuse visual-ﬁeld loss, more
marked in the inferior aspect of the ﬁeld (d). On review at 6 months, the optic disk swelling has resolved and the disk appears diﬀusely pale
and atrophic (e). Automated perimetry shows improvement in the superior visual ﬁeld, with a persistent inferior altitudinal defect (f).
Cardiacexaminationwasnormal,withoutarrhythmiaorany
sources of emboli.
Fundus examination revealed swelling and hyperemia of
the left optic disc with hemorrhage at superior and inferior
disc margins while the vessels, macula, and the peripheral
retina were normal (Figure 1). Humphrey visual ﬁeld (24-2
program) perimetry showed diﬀuse visual-ﬁeld loss, more
marked in the inferior aspect of the ﬁeld of the left eye
(Figure 1). Fundus ﬂuorescein angiography revealed hyper-
ﬂuorescence of the left optic disk and leakage from it,
indicating edema. There was no intraocular inﬂammation or
pathological disorders. The patient was not hyperopic, and
the cup-to-disk ratio in the fellow eye was 0.3.
Laboratory tests excluded diabetes, syphilis, and hyper-
coagulable states. Antinuclear antibodies and anticardiolipin
antibody tests were all negative. In addition, routine blood
tests, erythrocyte sedimentation rate, and C-reactive pro-
tein were in the normal range. There was, however, mild
dyslipidaemia (total cholesterol 248mg/dL; LDL 156mg/dL;
HDL 52mg/dL). Chest radiography was normal. A magnetic
resonance image scan of the brain and orbits with gadolin-
ium demonstrated normal optic nerves and no white matter
lesions. A Doppler ultrasound of the vertebral basilar arter-
ies, the external carotid arteries, and the common carotid
arteries did not reveal any signiﬁcant disorders as stenosis or
plaque. Neurological examinations were also normal.
The above-mentioned results led to the conclusion that
the patient had experienced a NAION attack on his left eye.
He was consulted to discontinue the use of sildenaﬁl citrate.
The patient was subjected to two subtenon injections of
betamethasone with a three-week interval in between.
Six months after the initial attack, visual acuity improved
to 8/10 for the left eye, the optic disk swelling has resolved,
and the disk appears diﬀusely pale, and atrophic automated
perimetry shows improvement in the superior visual ﬁeld,
with a persistent inferior altitudinal defect (Figure 1).
3. Discussion
NAIONisthemostcommonacuteoptic neuropathyinolder
age groups with an estimated annual incidence of 2.3 to
10.2 per 100,000 over 50 years of age, and 0.54 per 100,000
for all age [4, 5]. It is presumed to result from vascular
insuﬃciency at the optic nerve head leading to ischemia,
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unproven. The ﬁrst visual symptoms noticed by patients
with NAION are typically blurred vision, loss of part of
the visual ﬁeld, or both. A diﬀuse or focally swollen optic
disc is observed and multiple ﬂame-shaped hemorrhages are
usually present.
Hypovolemia, mainly due to severe surgical procedures
[6], atherosclerotic risk factors, [7], hypercoagulable states
[8],and crowded optic disk [9], in possible combination with
regional vascular endothelial disorders has been reported in
the pathophysiology of NAION.
The role of sildenaﬁl in causing injury to the optic nerve
is not known. Sildenaﬁl citrate is a selective phosphodi-
esterase 5 inhibitor causing vasomotor eﬀects through its
action on the nitric oxide-cyclic GMP pathway. Nitric oxide
is a potent vasodilator, and it physiologically regulates the
blood pressure. Inhibition of nitric oxide synthetase in an
animal model for glaucoma rescued retinal ganglion cell
from damage [10]. Although nitric oxide may play a role in
IOP regulation, sildenaﬁl did not cause an increase in IOP in
healthy male volunteers [11].
Several studies reported that there has been an increasing
number of case reports concerning patients who have devel-
oped NAION soon after the use of sildenaﬁl and other
phosphodiesterase type 5 inhibitors [12, 13]. It has been
hypothesized that these agents might exaggerate the phys-
iologic nocturnal hypotension resulting in ischemia to the
optic nerve head or that they might interfere with the
autoregulation of blood ﬂow thereby decreasing perfusion to
the optic nerve head [14].
In most of the cases of NAION after the use of sildenaﬁl,
patientsdetectedvisuallossuponawakeninginthemorning.
Elevated levels of sildenaﬁl and its active metabolite are
present in the blood for 8 to 12 hours after ingestion.
Therefore, if sildenaﬁl is ingested at night, suﬃcient drug
levels may be present during sleep or the next morning.
The majority of aﬀected users of phosphodiesterase type
5 inhibitors suﬀer already from other possible risk factors
for NAION. It is not possible to determine whether these
changes are directly related to sildenaﬁl, sexual activity, the
patient’s underlying cardiovascular, a combination of these
factors, or the other factors [15].
In the present case, the patient had mild hypercholes-
terolemia without any other vascular predisposing risk fac-
tors.However, the familyhistory of his fatherhaving suﬀered
from attacks of NAION indicates the possible presence of
anatomical or other unidentiﬁed risk factors for the devel-
opment of NAION.
The role of hereditary factors in familial NAION remains
unknown, and the only clinical diﬀerence between classical
and familial NAION is that the familial type seems to have
an earlier onset and a higher frequency of bilateral disease
[16].
This case might support the association between NAION
and the use of erectile dysfunction drugs. Many patients do
no disclose to their ophthalmologist information regarding
sildenaﬁl intake. Thus, Physician should directly ask about
the possible use of this medication and the presence of a
family history of NAION among other risk factors before
prescribing erectile dysfunction drugs and advising patients
to stop the drug if blurry vision occurs. Also, we recommend
that patients with a history of monocular NAION be cau-
tioned that sildenaﬁl may increase the risk of NAION in the
fellow eye.
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